Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

NodeGuardian · 2026-03-27T17:38:07+00:00

Apogee Therapeutics will hold a conference call on March 23, 2026, to discuss 52-week data from its Phase 2 APEX trial of zumilokibart for atopic dermatitis. The company focuses on innovative biologics for inflammatory conditions.

NodeGuardian

2026-03-27 17:38:07

Abstract generation in progress

Apogee Therapeutics will host a conference call and webcast on Monday, March 23, 2026, at 8:00 a.m. ET to discuss the Part A 52-week data from its Phase 2 APEX trial of zumilokibart (APG777) for patients with moderate-to-severe atopic dermatitis. The company, a clinical-stage biotechnology firm, specializes in advancing novel biologics for inflammatory and immunology markets. Zumilokibart is Apogee’s most advanced program, also being developed for asthma and eosinophilic esophagitis (EoE), aiming for best-in-class efficacy and dosing.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes